WO2007050631A3 - Forme posologique a enrobage actif - Google Patents

Forme posologique a enrobage actif Download PDF

Info

Publication number
WO2007050631A3
WO2007050631A3 PCT/US2006/041524 US2006041524W WO2007050631A3 WO 2007050631 A3 WO2007050631 A3 WO 2007050631A3 US 2006041524 W US2006041524 W US 2006041524W WO 2007050631 A3 WO2007050631 A3 WO 2007050631A3
Authority
WO
WIPO (PCT)
Prior art keywords
dosage forms
coated active
dosage form
active ingredient
orally dissolvable
Prior art date
Application number
PCT/US2006/041524
Other languages
English (en)
Other versions
WO2007050631A2 (fr
Inventor
Derek Moe
Zepeda Manuel A Vega
Original Assignee
Cima Labs Inc
Derek Moe
Zepeda Manuel A Vega
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cima Labs Inc, Derek Moe, Zepeda Manuel A Vega filed Critical Cima Labs Inc
Publication of WO2007050631A2 publication Critical patent/WO2007050631A2/fr
Publication of WO2007050631A3 publication Critical patent/WO2007050631A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne des formes posologiq ues pouvant se dissoudre/se désagréger par voie orale, qui sont conçues pour administration directe par voie orale et qui comprennent au moins un ingrédient enrobé actif obtenu par séchage par pulvérisation d'un ingrédient actif et d'un enrobage. Ces formes posologiques sont plus dures que celles, courantes, qui peuvent se dissoudre et se désagréger par voie orale, et leur intérêt réside dans leurs coûts de fabrication et de stockage.
PCT/US2006/041524 2005-10-25 2006-10-24 Forme posologique a enrobage actif WO2007050631A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73016805P 2005-10-25 2005-10-25
US60/730,168 2005-10-25

Publications (2)

Publication Number Publication Date
WO2007050631A2 WO2007050631A2 (fr) 2007-05-03
WO2007050631A3 true WO2007050631A3 (fr) 2007-11-01

Family

ID=37898582

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/041524 WO2007050631A2 (fr) 2005-10-25 2006-10-24 Forme posologique a enrobage actif

Country Status (1)

Country Link
WO (1) WO2007050631A2 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
CN102885791B (zh) * 2012-09-24 2015-03-04 浙江万晟药业有限公司 一种制备盐酸非索非那定口腔崩解片的方法
JP6539274B2 (ja) 2013-08-12 2019-07-03 ファーマシューティカル マニュファクチュアリング リサーチ サービシズ，インコーポレーテッド 押出成形された即放性乱用抑止性丸剤
CN111904924A (zh) * 2013-11-13 2020-11-10 财团法人国际教育基金会 化合物降低对乙酰氨基酚引起的肝毒性的用途及复方组合
WO2015095391A1 (fr) 2013-12-17 2015-06-25 Pharmaceutical Manufacturing Research Services, Inc. Comprimé extrudé anti-abus à libération prolongée
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
DK3169315T3 (da) 2014-07-17 2020-08-10 Pharmaceutical Manufacturing Res Services In Væskefyldt doseringsform til forhindring af misbrug med øjeblikkelig frigivelse
EP3209282A4 (fr) 2014-10-20 2018-05-23 Pharmaceutical Manufacturing Research Services, Inc. Forme galénique anti-abus de remplissage de liquide à libération prolongée
CN106511286B (zh) * 2016-10-27 2019-12-20 四川省百草生物药业有限公司 一种高稳定性的泛昔洛韦片及其制备方法
JP6858729B2 (ja) * 2018-05-25 2021-04-14 ▲財▼▲団▼法人国防教育研究基金会Ｎａｔｉｏｎａｌ Ｄｅｆｅｎｓｅ Ｅｄｕｃａｔｉｏｎ Ａｎｄ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ 肝臓に対する副作用がない、新しいアセトアミノフェン複合組成

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4631284A (en) * 1984-11-19 1986-12-23 Mallinckrodt, Inc. Acetaminophen compositions containing low doses of chlorpheniramine maleate, method for preparing same and tablets formed therefrom
US4710519A (en) * 1985-09-30 1987-12-01 Basf Corporation Process for preparing spray dried acetaminophen powder and the powder prepared thereby
US4904477A (en) * 1987-07-08 1990-02-27 American Home Products Corporation Spray dried ibuprofen compositions
US4952402A (en) * 1984-10-30 1990-08-28 Elan Corporation, P.L.C. Controlled release powder and process for its preparation
WO2000051568A1 (fr) * 1999-03-01 2000-09-08 Ethypharm Comprime orodispersible presentant une faible friabilite et son procede de preparation
WO2001089484A2 (fr) * 2000-05-22 2001-11-29 Verion, Inc. Procede pour augmenter la compressibilite de matieres pulverulentes a faible pouvoir de liaison

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4952402A (en) * 1984-10-30 1990-08-28 Elan Corporation, P.L.C. Controlled release powder and process for its preparation
US4631284A (en) * 1984-11-19 1986-12-23 Mallinckrodt, Inc. Acetaminophen compositions containing low doses of chlorpheniramine maleate, method for preparing same and tablets formed therefrom
US4710519A (en) * 1985-09-30 1987-12-01 Basf Corporation Process for preparing spray dried acetaminophen powder and the powder prepared thereby
US4904477A (en) * 1987-07-08 1990-02-27 American Home Products Corporation Spray dried ibuprofen compositions
WO2000051568A1 (fr) * 1999-03-01 2000-09-08 Ethypharm Comprime orodispersible presentant une faible friabilite et son procede de preparation
WO2001089484A2 (fr) * 2000-05-22 2001-11-29 Verion, Inc. Procede pour augmenter la compressibilite de matieres pulverulentes a faible pouvoir de liaison

Also Published As

Publication number Publication date
WO2007050631A2 (fr) 2007-05-03

Similar Documents

Publication Publication Date Title
WO2007050631A3 (fr) Forme posologique a enrobage actif
WO2008112124A3 (fr) Films administrables par voie orale
JP2009506080A5 (fr)
WO2007052299A3 (fr) Formulation pour liberation controlee
EP1995246A4 (fr) Derive heterocyclique azote et agent pharmaceutique comprenant le derive en tant que principe actif
PL2081547T3 (pl) Postać galenowa do podawania składników czynnych poprzez śluzówkę
EP2081550A4 (fr) Revêtement de capsules avec des ingrédients pharmaceutiques actifs
BR0309142A (pt) Formulação farmacêutica oral sob a forma de suspensão aquosa de microcápsulas que permitem a liberação modificada de princìpio(s) ativo(s)
FR2891459B1 (fr) Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant
WO2010123919A3 (fr) Inhibiteurs pipéridiniques de la janus kinase 3
WO2009100441A3 (fr) Formulations retard depot formulations
WO2010019587A8 (fr) Compositions de soin buccal contenant des billes
CL2007002686A1 (es) Compuestos derivados de 2h-isoquinolin-1-ona y 3h-quinazolin-4-ona, inhibidores de cinasa rho; y composicion farmaceutica, util para el tratamiento de una enfermedad o afeccion cardiovascular.
WO2010038237A3 (fr) Compositions présentant un transit retardé à travers le tractus gastro-intestinal
IL185926A (en) Annals of 2 - (3,1-Dihydro-H2-Benzimidazole-2-Illiden) -1-Alkylamidinosulfonylphenyl-3 - (Phenyl or Thienyl) -Propane-3,1
WO2009045795A3 (fr) Formulations galéniques de composés organiques
IL190698A0 (en) Nanoparticulate active ingredient formulations
WO2011140446A3 (fr) Formulations pharmaceutiques
WO2009120389A8 (fr) Préparations orales et injectables de composés de tétracycline
JP2007308378A5 (fr)
WO2006106519A3 (fr) Dispersions hydrophiles de nanoparticules de complexes d'inclusion de composes amorphes
WO2009122187A3 (fr) Composition pharmaceutique
JP2011500876A5 (fr)
EP1584335A3 (fr) Combinaison de substances actives comprenant un composé carbinol et un opioïde
IL208151A0 (en) Long-term stable pharmaceutical preparation having the active ingredient glycerol trinitrate

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06817354

Country of ref document: EP

Kind code of ref document: A2